ImmusanT cans phase 2 celiac trial after interim efficacy review by Nick Paul Taylor Wednesday, June 26, 2019 The analysis found Nexvax2 was no better than placebo at protecting patients from gluten, prompting the Arch-backed biotech to stop the study.
ImmusanT to move into Type 1 diabetes with JDRF backing by Conor Hale Tuesday, September 11, 2018 ImmusanT is expanding its vaccine immunotherapy platform to include Type 1 diabetes, following an investment from the JDRF.
Chutes and Ladders—Lilly's oncology chief announces retirement by Conor Hale Friday, May 25, 2018 Lilly’s oncology chief is retiring; a GSK vet is launching a Chinese public health startup; and Gilead’s R&D chief is going back to his roots.
ImmusanT goes on hiring spree ahead of celiac vaccine trial by Conor Hale Monday, May 21, 2018 ImmusanT recently expanded its senior staff, bringing on Daiichi Sankyo’s senior VP for internal medicine, Ken Truitt, as its chief medical officer.
ImmusanT's celiac disease immunotherapy passes first clinical test by Phil Taylor Wednesday, February 22, 2017 Celiacs could be freed from the gluten-free aisle of the supermarket if a therapeutic approach developed by ImmusanT proves effective in trials.
